QUEBEC CITY, June 29, 2011 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ) (the "Company"), a late-stage drug development company specialized in oncology and endocrine therapy, announced today that it has entered into an "At-the-Market" ("ATM") Sales Agreement, dated Jun
↧